Trial Profile

A Phase II Clinical Trial to Evaluate Amplige as Part of a Combination Therapy in Brain-Metastatic Breast Cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2020 According to an AIM ImmunoTech media release, the company expects to initiate this study in the 2020-21 .
04 Oct 2019 New trial record
24 Sep 2019 According to an AIM ImmunoTech media release, this and other phase II trial (CT profile 313473) are separate but parallel proposed clinical trials and are receiving approximately $15 million in DoD funding to study Ampligen as a tumor microenvironment modulating agent component of a dendritic cell vaccine approach in the treatment of brain-metastatic breast cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com